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 INTRODUCTION 
 
 Heart failure is the end stage of all diseases of the heart and is a major cause 
of morbidity and mortality. Since 1970s the treatment of CHF has been transformed, 
resulting in major benefit to patients.  This advance has been the consequence of 
better understanding of the pathophysiology, investigations, the introduction of 
newer drugs and cardiac transplantation.  The traditional treatment of heart failure 
with digoxin and diuretics has been replaced by  diuretics, ACE inhibitors and drugs 
directed against the origins of heart failure such as aspirin and lipid lowering drugs.  
Newer objectives are optimisation of the quality of life, avoidance of hospital 
admission prevention of progression of damage to the myocardium and prolongation 
of life. 
 
 So, it becomes important to conduct clinical and paraclinical studies to know 
about the status, precipitating factors and complications of the disease. Only with a 
reliable study changes in the modality of approach in controlling, diagnosing and 
treating the disease can be done. Here, an attempt has been made to study on selected 
aspects of congestive heart failure.   
 
 
 
 
 
 
  
 
 
AIMS AND OBJECTIVES 
 
1. To find out the prevalence of congestive heart failure among the 
patients admitted in the hospital. 
2. To analyse their presenting features & precipitating factors 
3. To correlate the clinical findings with the underlying etiology 
4. To study outcome of these cases during their hospital stay. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
REVIEW OF LITERATURE 
 
History : 
             Heart failure, angina and the pulse were known in the ancient Egyptian 
and early Greek civilizations. (Dallas 1993,  Horine  1941). Hippocrates described 
cardiac cachexia, most vividly reports of the benefits of foxglove exists in Roman 
literature. (Moore, 1985)  Hering used nitrate in 1853 to treat heart failure, the first 
use of a vasodilator.  Bruton later in 1867 described the use of amyl nitrate to treat 
angina. ACE inhibitors were shown to be of benefit in terms of mortality in patients 
with heart failure for the first time in 1987.  The large trail of  digoxin, showing no 
effect on overall mortality, was reported in 1996. 
 
 
 
 
 
 
 
  
Definitions of heart failure  
 
 1. A Pathophysiological state in which an abnormality of cardiac function is 
responsible for the failure of the heart to pump blood at a rate commensurate 
with the requirements of the metabolizing tissues (Braunwald  1994) 
2. Congestive heart failure represents a complex clinical syndrome, 
characterized by abnormalities of left ventricular function and Neurohormonal 
regulation, which are accompanied by effort intolerance, fluid retention and 
reduced longevity. (Packer 1988). 
3. Symptoms of heart failure, objective evidence of cardiac dysfunction and 
response to treatment directed towards the heart failure (Task force of the 
European society of cardiology 1995) 
 
EPIDEMIOLOGY: 
Heart failure is a relatively common disorder. It is estimated that 4.6 million 
persons in the United States are being treated for heart failure, with 550,000 new 
cases diagnosed each year.  (Dallas – 1999, Massie – 1977) 
 
 The prevalence of heart failure increases dramatically with age, occurring in 1 
to 2 percent of persons aged 50 to 59 and up to 10 percent of individuals older than 
the age of 75. (Ho et al 1993) 
 
 
 
  Approximately 80 percent of all heart failure admissions occur in patients 
older than 65, as a result, heart failure is the leading discharge diagnosis in persons 
65 years or older in the United States (Rich 1999) 
 Despite a steady decline in the incidence of coronary artery disease and 
stroke, both the incidence and prevalence of heart failure continue to rise. 
 Between 1985 and 1995 the number of heart failure hospitalizations increased 
by 5 percent and 8,70,000 hospital discharges for heart failure occurred in 1996.  
(Haldeman – 1999) 
 In the United States approximately 45,000 deaths each year are primarily 
caused by heart failure and heart failure is listed as a contributing cause in 260,000 
deaths (Dallas 1999) 
 In smaller mid western areas, recent assessment has suggested a prevalence as 
high as 6% of population. The same prevalence of 6-7 % also has been observed in 
Urban population.  (Senni et al – 1999) 
 The overall prevalence of heart failure is 3-20 per 1000 population although 
this exceeds 100 per 1000 in those aged 65 yrs and over.  The annual incidence of 
heart failure is 1-5 per 1000 and the relative incidence doubles for each decade of 
life after the age of 45 yrs. (Davis  Hobbs, Lip – 2003). The overall incidence is 
likely to increase in the future because of both an aging population and therapeutic 
advances in the management of acute myocardial infarction leading to improved 
survival in patients with impaired cardiac function. (Cowie et al – 1999). 
 Three major factors such as age, race and gender influence the prevalence and 
outcome in patients with heart failure. 
 
 Age : 
The most important factor is age.  The prevalence of CHF is less than 1% in 
patients <50 yrs of age regardless of gender.  At older than 50 years of age however, 
the prevalence increases to approximately 5% for patients between 50 and 70 years 
of age,  nearly 10% for all patients over 70 yrs of age and perhaps as high as 15% for 
patients over the age of 80.  
  The impact of age alone leads to a significant continued increase in the 
prevalence of heart failure as recent statistics have suggested that there will be a near 
doubling of patients over 65 years of age by the year 2030. (Dallas 2001). 
Race : 
 The second major influencing factor is race.  There has been a higher 
prevalence of heart failure in blacks compared to whites.   
  More importantly black patients develop heart failure at a younger age than 
white patients. (Bourassa et al 1993). 
 
Gender : 
 The third major factor influencing the heart failure is gender.  The national 
heart and nutrition education survey (NHANES) from 1988-1994 estimated that 
there is an increased prevalence of  congestive heart failure in men aged 70 years and 
younger. In contrast, women aged older than 70 years have a higher prevalence.  
This differences may be in part owing to the increased average life expectancy in 
women. (Anderson 2001). The highest prevalence of CHF is in black men followed 
by black women. 
 
 Data derived from the National centre of Health Statistics report that total life 
expectancy for the United States Population is 76.7 years.  Life expectancy is 73.8 
years for men and 79.5 years for Women (2000 estimate).  While the overall 
incidence of congestive heart failure is probably equal between the two genders, 
there are several unique features that may influence the prevalence of congestive 
heart failure in women, including a higher average ejection fraction for an equivalent 
amount of symptoms than men at all ages.  This may reflect a higher prevalence of 
hypertension in women with advancing age and almost certainly a higher prevalence 
of primary diastolic rather than systolic dysfunction. (Gheorghiade, Bonow 1998) 
 The Framingham data shows an age adjusted annual incidence of heart failure 
of 0.14% in women and 0.23 % in men.  Survival in the women is generally better 
than in the men. 
 
AETIOLOGY: 
The relative importance of aetiological factors in heart failure is dependent on 
the nature of the population being studied, as coronary artery disease and 
hypertension are common causes of heart failure in western countries, whereas 
valvular heart diseases and nutritional cardiac diseases are more common in the 
developing world. (Zannad – 1999) 
 
The common causes of heart failure include : 
1. coronary artery disease-MI, ischaemia 
2. hypertension 
3. cardiomyopathy 
 4. valvular and congenital heart diseases 
5. arrhythmias 
                       -tachycardias 
                       -bradycardia(CHB, sick sinus syndrome) 
6. alcohol and drugs 
        - alcohol 
        - cardiac depressant drugs (beta blockers and calcium channel  
blockers) 
7. high output failure 
                       - anaemia, thyrotoxicosis, av fistulas, paget’s disease 
8. pericardial diseases 
9. primary right heart failure 
      Pulmonary hypertension eg. pulmonary embolism, corpulmonale 
      Tricuspid incompetence 
 
Coronary artery disease and its risk factors: 
Coronary artery disease is the commonest cause of heart failure. In the studies 
of left ventricular dysfunction (SOLVD) Coronary artery disease accounted for 
almost 75% of the cases of chronic heart failure.   
  (Khadra Saleem, Rand 1998) Coronary artery disease and hypertension (either 
alone or in combination) were implicated as the cause in over 70% of cases of heart 
failure in the Framingham study. (Ho – 1993) 
 
Coronary risk factors, such as smoking and diabetes are also risk markers of 
the development of heart failure.  Smoking is an independent and strong risk factor 
 for the development of heart failure in men, although the findings in women are less 
consistent. 
In Framingham heart study, diabetes and left ventricular hypertrophy were the 
most significant risk markers for the development of heart failure.  Body weight and 
high ratio of total cholesterol concentration to high density lipoprotein cholesterol 
concentration are also independent risk factors for heart failure.  Clearly these risk 
factors may increase the risk of heart failure through their effects on coronary artery 
disease, although diabetes alone may induce important structural and functional 
changes in the myocardium, which further increase the risk of heart failure. 
 
Hypertension : 
Hypertension has been associated with an increased risk of heart failure in several 
epidemiological studies.  In the Framingham heart study, hypertension was reported 
as the cause of heart failure either alone or in association with other factors, in over 
70% of cases on the basis of non invasive assessment.  (Ho-1993). However 
hypertension is probably a more common cause of heart failure in selected patient 
groups, including females and black populations. Hypertension predisposes to the 
development of heart failure via  a number of pathological mechanisms, including 
left ventricular hypertrophy.  Left ventricular hypertrophy is associated with left 
ventricular systolic and diastolic dysfunction and an increased risk of myocardial 
infarction and it predisposes to both atrial and ventricular arrhythmias. 
Electrocardiograpic left ventricular hypertrophy is strongly correlated with the 
development of heart failure, as it is associated with a 14 fold increase in the risk of 
heart failure in those aged 65 years or under. 
  
Valvular heart disease : 
 Rheumatic heart disease may have declined in certain parts of the world,  but 
it still remains an important cause of heart failure in India and other developing 
nations. In the Framingham heart study, rheumatic heart disease accounted for heart 
failure in 2% of men and 3% women, although the overall incidence of valvular 
heart disease has been steadily decreasing in the Framingham cohort over the past 30 
years (HO – 1993).  
  MR and AS are the most common causes of heart failure, secondary to 
valvular disease.   MR and AR lead to volume overload, in contrast with AS which  
leads to pressure overload. The progression of heart failure in patients with  valvular 
heart disease is dependent on the nature and extent of the valvular disease.  In aortic 
stenosis heart failure develops at a relatively late stage and without, valve 
replacement, it is associated with a poor prognosis.  In contrast, patients with chronic 
mitral or aortic regurgitation generally decline in a slower and more progressive 
manner.  (Teerlink, et al 1991). 
 
Cardiomyopathies : 
Cardiomyopathies are defined as the disease of the heart muscle that are not 
secondary to coronary heart disease, hypertension or others.  As primary disease of 
heart muscle, cardiomyopathies are less common causes of heart failure, but 
awareness of their existence is necessary to make a diagnosis.  Cardiomyopathies are 
separated into four functional categories dilated, hypertrophic, restrictive and 
obliterative.  These groups can include rare specific heart muscle diseases such as 
 hemochromatosis in which cardiac involvement occurs as part of a systemic 
disorder.  Dilated cardiomyopathy is a more common cause of heart failure than 
hypertrophic and restrictive cardiomyopathies, obliterative cardiomyopathy is 
essentially limited to developing countries.  (Oakley 1997). 
Arrhythmias : 
 Cardiac arrhythmias are more common in patients with heart failure and 
associated  structural heart diseases, including hypertensive patients with left 
ventricular hypertrophy. 
 In the Hillingdon heart failure study 30% of patients presented for the first 
time with heart failure had atrial fibrillation and over 60% of patients admitted 
urgently with atrial fibrillation to a Glasgow hospital had echocardiographic 
evidence of impaired left ventricular function.  (Stevenson, 1995). 
  
Alcohol and drugs: 
 Alcohol has a direct toxic effect on the heart which may lead to acute heart 
failure or heart failure as a result of arrhythmias commonly atrial fibrillation.  
Excessive chronic alcohol consumption also leads to dilated cardiomyopathy. 
 Alcohol is the identifiable cause of heart failure in 2-3% of cases.  
Chemotherapeutic agents(doxorubicin) and antiviral drugs(zidovudine) have been 
implicated in heart failure, through direct toxic effects on the myocardium. (Maki et 
al – 1998) 
 
 
Endocrine causes : 
  High output heart failure is most often seen in patients with anemia and 
thyrotoxicosis. Myxedema may present with heart failure as a result of myocardial 
involvement or secondary to pericardial effusion. 
Corpulmonale : 
 Corpulmonale is defined as enlargement of the right ventricle secondary to 
abnormalities of the lungs, thorax, pulmonary ventilation or circulation.  It 
sometimes leads to right ventricular failure, with an elevation of transmural right 
ventricular end diastolic pressure. (Rich et al 2005). 
Pericardial Diseases : 
 Pericardial diseases like tuberculosis, CRF and malignant involvement may 
also cause congestive heart failure. 
Nutritional Causes : 
 Vitamin deficiency like wet beriberi, iron deficiency anaemia  and deficiency 
of hemopoeitic factors leading to heart failure, continue to produce a problem 
especially in developing countries like India. 
 
PATHOPHYSIOLOGY 
Heart failure is a multisystem disorder which is characterized by abnormalities of 
cardiac, skeletal muscle and renal function ; stimulation of the sympathetic nervous 
system; and a complex pattern of neurohormonal changes. 
 
 
 
Myocardial systolic dysfunction : 
  The primary abnormality in non valvular heart failure is an impairment in the 
left ventricular function, leading to a fall in cardiac output. The fall in cardiac output  
leads to activation of several neurohormonal compensatory mechanisms aimed at 
improving the mechanical environment of the heart. 
 
 Activation of the sympathetic system, for example tries to maintain cardiac 
output with an increase in heart rate, increased myocardial contractility and 
peripheral vasoconstriction (Increased catecholamines).   Activation of Renin 
angiotensin aldosterone system  also results in vasoconstriction and increase in blood 
volume, with retention of salt and water.  Concentration of vasopressin and 
natriuretic peptides increase.  Furthermore there may be progressive cardiac 
dilatation or alterations in cardiac structure (remodelling) or both. (Borgeon, 
Burnett 1997) 
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Effects of Sympathetic nervous system on heart failure : 
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RAAS  : 
 Stimulation of the RAAS leads to increased concentration of renin,  
angiotension II and aldosterone.  Angiotension II is a potent vasoconstrictor of the 
renal and systemic circulation where it stimulates release of noradrenaline from 
sympathetic nerve terminals  which inhibits vagal tone and promotes the release of 
aldosterone.  This leads to the retention of sodium and water.  In addition, 
angiotension II has an important effects on cardiac myocytes and may contribute to 
the endothelial dysfunction that is observed in chronic heart failure. (Francis et al, 
1990) 
 
Sympathetic nervous system : 
 The sympathetic nervous system is activated in heart failure via low and high 
pressure baroreceptors, as an early compensatory mechanism which provides 
Activation of sympathetic nervous system 
RASS Vaso 
Constriction 
Increased HR & 
contractility
Direct Cardiac 
toxicity 
Fluid 
retention 
Increased 
wall stress 
Increased myocardial 
oxygen demand 
myocardial  
     damage
Myocardial hypertrophy
 decreased 
contractility 
 inotropic support and maintains cardiac output.   In the long term, the ability of the 
myocardium to respond to chronic high concentration of catecholamines is 
attenuated by a down regulation in beta receptors. This may be associated with 
baroreceptor dysfunction and a further increase in sympathetic activity.  (Schoffer et 
al, 1987). 
 
Natriuretic peptide: 
 There are 3 natriuretic peptides of similar structure and these exert a wide 
range of effects on the heart, kidneys and central nervous system. 
 Atrial natriuretic peptides is released from the atria in response to stretch, 
leading to natriuresis and vasodilatation. In humans, brain natriuretic peptide (BNP) 
is also released from the heart (mainly from the ventricles) and its actions are similar 
to those of ANP. C-type natriuretic peptide is limited to the vascular endothelium 
and central nervous system and has only limited effects on natriuresis and 
vasodilatation.  (Van cheng et al, 2001 &  Moe et al, 1993.) 
Vasopressin: 
 Vasopressin concentration is also increased in severe chronic heart failure.  
High concentrations of the hormone are particularly common in patients receiving 
diuretic treatment and this may contribute to the development of hyponatremia. 
(Francis et al, 1990 & Goldsmith, 1986). 
Endothelin : 
 Endothelin is secreted by vascular endothelial cells and is a potent 
vasoonstrictor on the renal vasculature, promoting the retention of sodium and water.  
Endothelin concentration is also correlated with indices of severity such as the 
 pulmonary artery capillary wedge pressure need for admission to hospital and death.  
(Tsutamoto et al, 1995) 
In view of the vasoconstriction properties of endothelin interest has developed 
in endothelin receptor antagonist as cardio vascular protective agents which inhibit 
endothelin mediated vascular and myocardial remodelling.  (Yanagisawa et al, 
1988). . 
Patterns of neurohormonal activation and prognosis : 
Asymptomatic LV dysfunction : 
 Plasma norepinephrine concentrations increase early in the development of 
left ventricular dysfunction and plasma renin activity usually increases in patients 
receiving diuretic treatment. Norepinephrine concentration in asymptomatic LV 
dysfunction is a strong and independent predictor of the development of 
symptomatic heart failure and long term mortality. 
 In severe untreated chronic heart failure, concentrations of renin, angiotension 
II, aldosterone, noradrenaline and ANP are all increased.   Plasma concentrations of 
various neuroendocrine markers correlate with both the severity of heart failure and 
the long term prognosis. Patients with chronic heart failure and raised plasma 
noradrenaline concentrations do also have a worse prognosis. (Esler 1997) 
 
 
 
Effect of ACE inhibitor in CHF:  (Yusuf et al 2000) 
   
    
Myocardial/valvular damage 
  
 
 
 
 
 
      
 
 
        ACE inhibitor 
    
 
 
 
 
Diastolic dysfunction: 
 Diastolic heart failure refers to the clinical syndrome of HF with a preserved 
left ventricular ejection fraction (0.50 or more) in the absence of major valvular 
disease. The pathophysiology of diastolic heart failure characterized by a low cardiac 
output that results typically from a ventricle that has  thick walls but a small cavity 
(increased LV mass). The left ventricular cavity is stiff.  It relaxes slowly in early 
diastole and offers greater resistance to filling in late diastole, so that diastolic 
pressure is elevated.  The low cardiac output manifests as fatigue, while the higher 
end diastolic pressure is transmitted backwards through the valveless pulmonary 
veins to the pulmonary capillaries, resulting in exertional dysponea. (Vasan, Levy 
2000). Mechanisms contributing to abnormal left ventricular diastolic properties 
include, stiff arteries, hypertension, ischaemia, diabetes and intrinsic myocardial 
Decreased ventricular 
performance 
arrhythmias 
Decreased CO 
Increased LV after load Activation of neurohormonal 
systems 
Increased vascular resistance / 
 Sodium retention 
 changes with or without associated hypertrophy. (Kitzman et al 2002). The prognosis 
of diastolic heart failure is generally better than that of systolic HF. 
Diastolic heart failure is common in clinical practice.  The   diagnosis of 
diastolic heart failure may be considered in patients with HF who have a normal LV 
ejection fraction (0.50 or more).  Prevention of diastolic heart failure can be achieved 
through better control of hypertension and other cardiac vascular  risk factors in the 
community. (Ibrahim 2003). 
The  pathophysiological abnormalities trigger neurohormonal activation as 
happens in systolic heart failure.  Symptoms may be unmasked by exercise, because 
unlike normal people, patients with diastolic heart failure are unable to augment their 
stroke volume by increasing their left ventricular diastolic volume.   
Myocardial dysfunction due to remodelling, hibernation and stunning: 
 After extensive myocardial infarction, cardiac contractility is frequently 
impaired and neurohormonal activation leads to regional eccentric and concentric 
hypertrophy of the non-infarcted segment, with the expansion of the infract zone. 
This is known as ventricular remodelling. Particular risk factors for this development 
of progressive ventricular dilatation after a myocardial infarction include a large 
infarct, anterior infarctions, occlusion of the artery related to the infarct and 
hypertension. 
 Myocardial dysfunction may also occur in response to stunning (post 
ischaemic dysfunction) which describes delayed recovery of myocardial function, 
despite restoration of coronary blood flow, in the absence of irreversible damage. 
This is in contrast to ‘hibernating’ myocardium, which describes persistent 
myocardial dysfunction at rest, secondary to reduced myocardial perfusion although 
 cardiac myocytes remain viable and myocardial contraction may improve with 
revascularization. (Rahimtoola 1989) 
 
Process of ventricular remodeling 
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Increased wall stress 
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Types of heart failure : 
Forward failure : 
 Forward failure developes due to marked reduction of left ventricular output 
and cardiogenic shock occurs. (Mechenzie J. 1913) 
 
 
Backward failure : 
 Small transient inequality of output between the two ventricles resulting in 
acute pulmonary edema. 
Right sided heart failure : 
 Due to stagnation of blood in the right side of heart and lungs right heart 
failure signs develop. 
 Left sided heart failure : 
 Due to poor cardiac output in aortic stenotic lesion or massive MI the left 
sided heart failure develops. 
Acute heart failure Vs chronic heart failure : 
 The clinical manifestations of HF depends mainly on the rate at which the 
syndrome develops and specifically  whether sufficient time has elapsed for 
compensatory mechanisms to become operative and for fluid to accumulate in the 
interstitial space. 
Low output Vs high output failure : 
 Heart failure occurring in low cardiac output  at rest or in milder cases during 
exertion characterizes most  forms of cardiovascular diseases. 
 High output heart failure occurs in variety of high output states like 
thyrotoxicosis, paget’s disease, AV fistulas, anaemia and beriberi. (Stevenson 1989). 
Systolic Vs diastolic HF : 
 Implicit in the physiological definition of heart failure (inability to pump an 
adequate volume of blood and or to do so only from an abnormally elevated filling 
pressure) is that heart failure can be caused by an abnormality in systolic function 
leading to a defect in expulsion of blood leading to systolic heart failure or by an 
abnormality in diastolic function leading to a defect in ventricular filling (diastolic 
failure). This may be due to slowed or incomplete ventricular relaxation, which may 
be transient as occurs in ischaemia, or sustained, as occurs in concentric myocardial 
hypertrophy or restrictive cardiomyopathy secondary to infiltrative conditions like 
amyloidosis. 
  The principal clinical manifestations of systolic failure result from an 
inadequate cardiac output and secondary  salt and water retention – forward heart 
failure. (Gaasch 1994) 
Whereas the major consequence of diastolic HF is related to the elevation of 
ventricular filling pressure and the high venous pressure upstream to the ventricular 
cavity, causing pulmonary and systemic congestion (backward failure). (Vasan 
1995). 
Clinical features and complications : 
 Patients with HF present with a variety of symptoms, most of which are 
nonspecific. The common symptoms of congesitive HF include fatigue, dyspnoea, 
pedal edema and exercise intolerance or symptoms that relate to the underlying 
cause. 
Symptoms and signs in heart failure : 
Symptoms 
 Dyspnoea 
 Orthopnoea 
 Palpitation 
 Chest pain 
 PND 
 Reduced exercise tolerance, lethargy, fatigue 
 Nocturnal cough 
 Wheeze 
 Ankle swelling 
 Anorexia 
Signs 
  Cachexia and muscular wasting 
 Tachycardia 
 Pulsus alternans 
 Increased JVP 
 Displaced apex beat 
 RV heave 
 Crepitations or wheeze 
 3rd heart sound 
 Oedema 
 Hepatomegaly, ascites 
Symptoms : 
Dyspnoea  
 Exertional breathlessness is a frequent presenting symptom in heart failure, 
although it is a common symptom in patients with pulmonary disease. Dyspnoea is 
therefore moderately sensitive but poorly specific for the presence of HF. 
Orthopnoea is a more specific symptom. PND results from increased LV 
filling pressure and therefore has a greater sensitivity and predictive value. (Manning 
1995). 
Fatigue and lethargy 
 Fatigue and lethargy in CHF are due to impaired muscle blood flow and 
deficient endothelial function. (Manchini 1994) 
 
Oedema 
  Swelling of ankles and feet is another common presenting feature.  Heart 
failure may manifest as oedema, right hypochondrial pain (liver congestion), 
abdominal distension(ascites) and loss of appetite(due to bowel congestion). An 
increase in weight may be associated with fluid retention although cardiac cachexia 
and weight loss are important markers of disease severity. (Milne 1985) 
 
Physical signs : 
 Physical examination has serious limitations as many patients particularly 
those with less severe heart failure, have few abnormal signs. In addition, some 
physical signs are difficult to interpret, and if present, may occasionally be related to 
causes other than HF. 
 
 Oedema and a tachycardia, for example are too insensitive to have any useful 
predictive value and although pulmonary crepitations  may have a high diagnostic 
specificity. Increased JVP has a high specificity in diagnosing HF in patients who are 
known to have cardiac disease. 
 Displaced apex beat in patients with myocardial infarction and 3rd heart sound 
have a relatively high specificity. 
 
Precipitating factors of heart failure : (Ghali 1988) 
1. iatrogenic cause – NSAID’s and steroids 
2. arrhythmias, especially atrial fibrillation 
3. infection especially pneumonia 
4. acute myocardial infarction 
 5. angina pectoris or recurrent myocardial ischaemia 
6. anaemia 
7. alcohol excess 
8. poor drug compliance especially in antihypertensive treatment. 
9. thyroid disorders – thyrotoxicosis 
10. pulmonary embolism 
11. pregnancy 
12. Excess water intake 
13. Exertion 
14. Excess salt consumption due to prepared dishes 
 
European society of cardiology guidelines for diagnosis of heart failure : 
Essential features : 
Symptoms of heart failure (eg breathlessness, fatigue, swelling) 
and objective evidence of cardiac dysfunction at rest. 
Nonessential features : 
Response to treatment directed towards heart failure (in cases where the 
diagnosis is in doubt) 
 
Complications of heart failure: 
1. Arrhythmias  
Atrial fibrillation: 
 AF that occurs with severe left ventricular dysfunction following myocardial 
infarction is associated with a poor prognosis. In addition patients with heart 
 failure and atrial fibrillation are at particularly high risk of stroke and other 
thromboembolic complications. (Skinbane 1997). 
Ventricular arrhythmias 
Malignant ventricular arrhythmias are common in end stage HF, sustained 
monomorphic VT occurs in upto 10% of patients with advanced heart failure. 
 
2. Stroke and thromboembolism: 
 CHF predisposes to stroke and thromboembolism with an overall estimated 
annual incidence of approximately 2%. Factors contributing to the increased 
thromboembolic risk in patients with HF include low cardiac output  regional wall 
motion abnormality and associated atrial fibrillation.  (Zuccala 1997) 
Prognostic factors in CHF: 
Most long term(>10 yrs of followup) longitudinal studies of HF , including 
the Framingham heart study(1971) were performed before the widespread use of 
ACE inhibitors. In the Framingham study overall survival at 8 years for all NYHA 
classes was 30%. The prognosis in patients whose LV dysfunction is asymptomatic 
is better than that in those whose LV dysfunction is symptomatic 
  The prognosis in patients with CHF is dependent on severity, age and sex 
with a poorer prognosis in male patients. In addition numerous prognostic indices are 
associated with an adverse prognosis, including NYHA class, LV ejection fraction 
and neurohormonal status. 
 Survival can be prolonged in chronic heart failure that results from systolic 
dysfunction, if angiotension converting enzyme inhibitors are given.  (Consensus 
1987) 
 Some predictors of poor outcome in chronic heart failure: 
1. high NYHA functional class 
2. reduced LV ejection fraction 
3. low peak oxygen consumption with maximal exercise 
4. third heart sound 
5. increased pulmonary artery capillary wedge pressure 
6. reduced cardiac index 
7. diabetes mellitus 
8. reduced sodium concentration 
9. raised plasma catecholamine and natriuretic peptide concentrations. 
Sudden death: 
 Sudden death may be related to ventricular arrhythmias although asystole is a 
common terminal event in severe heart failure. (Feldman 1988). 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
  
Setting     : The present work was carried out at the 
    Dept. of Medicine and Cardiolgy, 
Govt. Rajaji Hospital and  
Madurai  Medical College,  Madurai. 
  
Collaborating Departments : The work was carried out in  
      colloaboration with 
Dept. of Cardiology, 
      Govt. Rajaji Hospital and 
      Madurai Medical College, Madurai. 
 
Design of Study   : Cross sectional study 
Period of Study   : May 2005  to  Nov 2005 
Sample size    : 196 patients 
Ethical committee approval : The present project was approved by  
the ethical committee. 
Inclusion criteria : 
 All cases of proved congestive heart failure admitted in medical wards of 
Govt. Rajaji Hospital, Madurai. 
 
Exclusion Criteria : 
1. All cases under anti failure treatment 
2. Cases admitted in other wards apart from medical wards 
3. Patients less than 12 years of age 
4. Pregnant women 
 
Consent : 
 Informed consent was obtained from all those who participated in the study or 
their relatives 
Materials : 
 Thus a total of 196 cases who satisfied the inclusion and exclusion criteria 
stated above were taken  up for subsequent study. 
  
Definitions used for the study : 
1. Congestive heart failure : 
 Heart failure is the state of any heart diseases in which despite, adequate 
ventricular filling, the cardiac output is decreased or in which the heart is unable to 
pump blood at a rate adequate for satisfying the requirements of the tissues. (Zipes et 
al 2004) 
2.  Dyspnoea : 
 Undue awareness of ones own breathing. Dyspnoea is a cardinal 
manifestation of left ventricular failure. (Zipes et al, 2004) 
3.  Smoking : 
 The subject was considered to be a smoker if he / she gave a history of 
tobacco smoking with in the past 20 years.  Persons who had quit smoking 
completely before 20 years were not considered as smokers. (IARC Vol 83, 2003) 
4. CAD   
 Those patients who are having ECHO evidence of regional wall motion  
abnormality are diagnosed as coronary artery disease patients. 
 
5.  RHD  
 Those patients who are having ECHO evidence of valvular abnormalities are 
diagnosed as rheumatic heart disease patients. 
 
6.  Systemic Hypertension : 
   A subject was considered to have systemic hypertension if he/she was 
already diagnosed to have systemic hypertension and was on anti hypertensive 
medication or if the systolic blood pressure during the hospital stay was found to be 
more than or equal to 140 mm Hg and / or the diastolic blood pressure was more 
than or equal to 90 mm Hg according to the JNC VII report. (Chobanian et al 2003) 
 
7. Anaemia : 
  Anaemia may be defined as a state in which the blood Hb level is 
below the normal range for the patients age and sex (males < 12 gms )  Non pregnant 
females < 11.5 gms) 
8. Diabetes Melitus : (American Diabetes association 2004) 
 A subject was considered to have diabetes mellitus if he / she was already 
diagnosed to have diabetes mellitus or during the hospital stay was found to have a 
 - Fasting plasma glucose of   > 126 mg /dl 
     or 
 - 2 hours PP plasma glucose   > 200 mg / dl 
 - Symptoms of diabetes mellitus plus  
random blood sugar             >  200 mg / dl   
 
9. Left ventricular dysfunction :  (Colucci et al 2001) 
 Left ventricular dysfunction was divided in to mild, moderate, severe 
according to ejection fractions in ECHO. 
       < 29%    Severe 
30-39 Moderate 
 40-49 Mild    
10. BMI : 
 BMI is the convenient and reliable indicator of body fat which is the body 
weight in kilograms divided by square of height in meters. 
  
 >25      all abnormal 
 25 - 30 Over weight 
 > 30  obese 
 > 35  Markedly obese 
 
11. Waist Hip Ratio : 
  It is an approximate index of  intra abdominal fat mass and total body 
fat.  High WHR (> 1.0 in men and > 0.85 in women) indicates abdominal fat 
accumulation.  (Charney et al, 1976) 
 
12. Cardiomyopathy : 
 Cardiomyopathy is a group of diseases that affect the heart muscles itself and 
not the result of HT or congenital or acquired valvular, coronary or pericardial 
abnormalities.  (Zipes et al 2005) 
13. Cor – pulmonale  : 
  Corpulmonale is defined as enlargement of right ventricle secondary to 
abnormalities of the lungs, thorax, pulmonary ventilation or circulation.  It 
sometimes leads to RV failure, with an elevation of transmural RV end diastolic 
pressure.  (Zipes et al 2005) 
 14. Drug Intake :  (NSAIDs) 
 Consumption of NSAIDs was considered as a precipitating factors , in those 
patients who developed CHF after taking NSAIDs in the recent past.  All the other 
possible precipitating factors were excluded. 
15.Infection 
 Infection was considered as a precipitating factor in  those patients who 
developed CHF and presented with features of acute infection which was confirmed 
by clinical and laboratory means. 
16. Diet : 
 Diet was considered as a precipitating factor in those patients who developed 
CHF due to intake of salt rich food like dried fish, chips and pickles,  when the other 
factors were excluded. 
17. Arrhythmias : 
  Arrhythmias was considered as a precipitating factor in those CHF 
patients who had clinical and ECG evidence of  arrhythmias. 
Methods : 
 Selected socio-demographic, clinical and laboratory data were collected from 
the patients and recorded in a proforma (enclosed in Appendix) 
 
I Socio – demographic data comprised of 
 1. Age 
 2. Sex 
 3. History of tobacco smoking 
II   Clinical Data : 
  Clinical Examination 
III Laboratory Data : 
 Hb 
 Blood sugar, Urea, Creatinine 
 ECG 
 ECHO 
Hb :  
 Sahlis Haemoglobinometer was used for Hb estimation. 
ECG 
 12 lead multi channel ECG was taken in all the patients. 
ECHO : 
 Transthoracic Echo was done using ALOKO PROS 100 in all the cases.   
ECHO, M – MODE  ECHO was done to analyse  regional wall motion abnormality, 
presence of clot and  to assess the left ventricular function.  Colour Doppler 
evaluation was done to evaluate the presence of valvular regurgitation and also to 
assess the diastolic function. 
Conflict of interest : 
 Nil 
Financial Support : 
 Nil 
Limitations : 
1. There is no definite parameter to measure the serum drug level in patients 
with drug intake. 
2. B – Natriuretic and ANP levels could not  be measured. 
Statistical Analysis : 
  Data were entered in Microsoft Excel spread sheet and analysed utilizing the 
software – Epidemiological Information Package 2002  developed by the Centre for 
disease control and prevention, Atlanta for World Health Organization.  Range, 
Median, Mean,  Standard Deviation and ‘p’ values were calculated using this 
package.  Chi-square test was done to find out the significance of relationship 
between the groups.  Significance was considered if the ‘p’ value was below 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
  During the study period, 6072 patients were admitted in the medical 
wards.  Out of them 196 satisfied the inclusion criteria.  So the prevalence was 3.2 %  
(196/6072). 
  Among the 196, 7 were expired, thus case fatality rate was 3.5%.  (7/196).   
Disposition of Study Subjects 
 
 
 
 
 
 
 
 
 
  On treatment (30 cases) 
  Pregnant women (9cases)  Exclusion criteria 
  Not willing for the study (5 cases) 
 
 
          
Satisfied our inclusion criteria 
 
 
  
 
 
Distribution of cases in relation to age group and gender is produced in Table 
No. 1 given below. 
Table – 1  -  CHF  Age  and Gender Distribution Chart 
Cases screened 
6072 cases in Medical 
Admission
Cardiac 
346 
Non Cardiac 
5726 
With CHF 
240 
Without CHF 
106 
196 
106 Males 
90   Females 
 Age Male Female Total 
15-24 5  15 20 
25-34 8 9 17 
35-44 16 19 35 
45-54 21 18 39 
55-64 34 19 53 
65-74 15 8 23 
75-84 5 2 7 
85-94 2 0 2 
Total 106 90 196 
 
Mean 43.67 52.03 48.9 
S.D 16.89 14.98 16.39 
Median 55 45  
  
In the present study median age affected by CHF among male was 55 years, 
among female was 45 years and in general it was 50 years. 
  
 
 
 
In the present study, among 196 CHF patients , 92 patients (47%) were under 
the age group of 45 to 65.   Among these, males were affected more, approximately 
60%.  The remaining patients were females. 
  
 
Table – 2    -    CHF gender variation 
Sex Observed Expected 
Male 106 182 
Female 90 122 
Total 196 304 
  
 P = 0.072 
 P > 0.05   Not significant 
 
 
 
 
 
 
 
 
 
 
In the present study various presenting features of CHF were elicited.  The 
details are shown in the table no. 3 below. 
 
Table – 3   CHF -  PRESENTING FEATURES and GENDER 
 (Overlapping with each other) 
 Male Female Total Proportion 
Dyspnea 106 88 194 0.99 
Palpitation 78 77 155 0.79 
Chest pain 83 77 160 0.82 
Pedal edema 101 83 184 0.94 
Abdominal Pain 65 66 131 0.67 
Abd. distension 49 60 109 0.56 
Oliguria 83 68 151 0.77 
Pulmonary rales 104 88 192 0.98 
Hepatomegaly 67 62 129 0.66 
 
 
 
 
 
 
 
 
Table :  4 
CHF  :   CAD  Vs Presenting features 
 CAD with symptoms CAD without symptoms 
Dyspnoea 76 6 
Pedal edema 66 16 
 Chest pain 70 12 
 
 X2      - 5.2497 
 P value - 0.0220 
 P is   <  0.05  significant 
 In the present study, the most common presenting feature was dyspnea (99%) 
and the sign was pulmonary rales(98%).   The second most common presenting 
features was pedal edema (94%). 
 
 
 
 
 
 
 
 
 Careful elicitation of the precipitating factors helped to identify the conditions 
in order to eliminate or overcome the same during therapy.  During the present study 
various precipitating factors were identified.  The details are shown in Table No. 5. 
 
Table – 5  -  CHF – Precipitating Factors 
 Male Female Total 
Diet 19 11 30 
Drug 44 42 86 
 Anaemia 18 12 30 
Infection 18 16 34 
Arrhythmias 7 9 16 
Total 106 90 196 
  
 Among the 196 patients, 86 patients were taking  one or more drugs  for the 
underlying disease.  
Out of 196  patients 34 patients were had some form of  infection.  30 patients 
had anaemia. 
 Arrthymia was a precipitating factor in 16 (M-7, F-9) out of 196 patients. 
 
 
 
 
 
 
Various etiological factors were analysed in the study.  The details are shown  
below in Table – 6 
 
Table – 6  :  CHF  -  Etiological factors 
 Male Female Total 
CAD 71(86.5%) 11(13.5%) 82 
RHD 12(25%) 36(75%) 48 
Systemic HT 12(40%) 18(60%) 30 
 CM 3(17%) 15(83%) 18 
Corpulmonale 8(44%) 10(56%) 18 
Total 106 90 196 
 
In the present study, out of 196 CHF patients, 82 were due to CAD, 48 were 
due to RHD and 30 were due to systemic hypertension.   
 Other causes were cardio myopathy 18 and corpulmonale 18. 
  Out of 30 CHF patients due to Systemic hypertension, 18 were females.  
 
 
 
 
 
 
 
 
In the present study waist circumference of the CHF patients were given 
below in  table no. 7 
 
Table No. 7  :   CHF  Waist circumference 
 
Waist Circumference Male Female Total 
<  80 cm 38 (51%) 36(49%) 74 
80 – 84.9 49 (58%) 36(42%) 85 
 85 – 89.9 14 (50%) 14 (50%) 28 
90-94.9 4 (80%) 1 (20%) 5 
95 – 99.9 1 (33%) 2 (67%) 3 
> 100 0 (0%) 1(100%) 1 
Total 106 90 196 
 
 Out of 196 patients 113 had waist circumference between 80-90 cms. 
  
 
 
 
 
 
CHF precipitated by various factors were analysed individually, the figures 
are given below. 
Table 8  :  CAD Vs Drug Intake 
Sex CAD due to drug 
intake 
CAD due to other 
precipitating factors 
Total 
Male 33 38 71 
Female 7 4 11 
Total 40 42 82 
 
 X2    =   1.1222 
 P = 0.02894 
 P      >  0.05 not significant. 
Among  82 CHF patients due to CAD,  40 patients, heart failure was precipitated by 
NSAIDs  intake. 
  
Table No. 9   : RHD  Vs   Drug Intake 
Sex RHD due to drug 
intake 
RHD due to other 
precipitating factors 
Total 
Male 5 7 12 
Female 17 19 36 
Total 22 26 48 
 
X2  = 0.1119 
P value = 0.738 
P is  >  0.05     not significant 
Among 48 CHF patients due to RHD in 22 patients it was precipitated by NSAIDs 
intake. 
 
Table No. 10  :   Systemic hypertension Vs  Drug intake 
Sex Sy.HT due to drug 
intake 
Sy.HT due to other 
precipitating factors 
Total 
Male 2 10 12 
Female 13 5 18 
Total 15 15 30 
 
X2   = 8.8889 
P value =  0.0029 
P  < 0.05  It is significant. 
Among the 30 CHF patients due to systemic HT, 15 patients failure was 
precipitated by drugs like NSAIDs 
 
Table – 11   :   CAD Vs  Infection 
Sex CAD precipitated by 
Infection 
CAD precipitated by 
Others 
Total 
 Male 11 60 71 
Female 1 10 11 
Total 12 70 82 
 
X2    =   0.3125 
P value  =   0.5762 
P is > 0.05   not significant 
In 82 patients with CHF due to CAD only 12 patients, heart failure was 
precipitated by an acute infection. 
 
 
 
Table :  12    -  RHD  Vs  Infection 
  
Sex RHD precipitated by 
Infection 
RHD precipitated by 
Others 
Total 
Male 3 9 12 
Female 8 28 36 
Total 11 37 48 
 
P value 
X2     - 0.0393 
P value  - 0.8428 
P is  >  0.05   not significant 
Among 48 CHF patients due to RHD  11 patients, heart failure was 
precipitated by Infection. 
Table  :   13      
CHF-  Systemic HT  Vs  Infection 
 Sex Sys HT precipitated 
by infection 
Sys HT precipitated by 
others 
Total 
Male 3 9 12 
Female 2 16 18 
Total 5 25 30 
 
X2      - 0.999 
P value - 0.3173 
P  is    >  0.05   Not significant 
Out of 30 CHF patients due to Systemic HT 5 had failure precipitated by 
acute infection. 
 
Table No :  14     
CHF -  CAD Vs  Diet 
Sex CAD precipitated by 
Diet 
CAD precipitated by 
Others 
Total 
Male 13 58 71 
Female 0 11 11 
Total 13 69 82 
 
 X2 = 2.3935 
 P value= 0.1218 
 P is  >  0.05  Not significant 
Out of 82 CHF patients due to CAD, 13 patients heart failure were 
precipitated by salty foods like fried fish. 
 
Table  :  15 
 CHF - CAD  Vs  Arrythymias 
Sex CAD precipitated by 
Arrhythmias 
CAD precipitated by 
Arrythymias 
Total 
 Male 5 66 71 
Female 2 9 11 
Total 7 75 82 
 
 X2  - 1.5137 
 P value - 0.2186 
 P is > 0.05  Not significant 
 Out of 82 CHF patients,  due to CAD  7 patients had heart failure  precipitated 
by arrythymias. 
 
Table :  16  CHF   -    RHD  Vs  Arrhythmias 
Sex RHD precipitated by 
Arrhythmias 
RHD precipitated by 
Others 
Total 
Male 0 12 12 
Female 4 32 36 
Total 4 44 48 
  X2    - 1.4545 
 P value  - 0.2278 
 P is  >  0.05  Not significant 
 Out of 48 CHF patients due to RHD, 4 patients heart failure was precipitated 
by Arrythymias. 
BMI was calculated in patients belonging to different categories of heart 
failure and the  details are shown in Table No. 17. 
 
Table No. 17    CHF -   BMI   
 CAD NON CAD  
BMI MALE FEMALE MALE FEMALE T 
0-15 1 0 0 0 1 
 15-20 2 3 5 6 16 
20-25 21 12 29 37 99 
25-30 25 11 18 18 72 
30-35 3 2 2 1 8 
Total 52 28 54 62 196 
 
Out of  196 CHF patients, 171 patients,  BMI was between 20-30. 
 
DISCUSSION 
 
 Heart failure has been the number one cause for death in every year during the 
past century, while death from CAD and stroke has been decreasing over the past 
decade, there has been a significant increase in the prevalence of morbidity and 
mortality from CHF. 
 
 Data from Framingham study suggest that the estimated prevalence of CHF 
ranges from 2% to 6%.  In smaller mid western areas the prevalence rate is as high as 
6% of population. The prevalence of CHF  in the present study was 3.2% 
 
A comparative analysis given below in Table No. 18 
Table - 18 
CHF comparative Analysis 
 
Sl No. Details of study Prevalence Remarks 
 1. Framingham Study 2  to  6 % Population based study 
2. Present study 3.2 % Hospital based study 
 
 The prevalence is lower in the present study comparing to western studies. 
 
 
 
 
 Following causes have been identified for the low prevalence of CHF in the 
present study: 
1. Hospital bias – highly selected hospital  services 
2. Referral system :   Critical cases are referred from primary and secondary, 
care centres to the  tertiary care unit. 
3. Facilities :  In western countries increased awareness has helped critical 
cases to be referred immediately to the hospital. 
4. In our health care system,  the medical college hospitals, that are supposed 
to the tertiary care centres  provide  primary, secondary and tertiary care 
services. So referrals are not uniform. 
5. Complexity  of cases :  Variety of problems related to Infections, Toxic 
related and degenerative disorders, contribute to the admission.  So the 
true prevalence gets altered. 
 
 From population studies, Sulton Gc et al observed, CHF is less than 1% for 
patients  <  50 years and the  prevalence increases to approximately 5% for patients 
 between 50-70 years of age,  whereas it was  10% for all patients over the age of 70 
years. 
 
 In the present study prevalence among the age group  45 - 54  comes around 
20%,  55-64 comes to 27%, and  65-74  comes  12% 
 
 
 
 Comparing to Western data, in our study,  prevalence of CHF is decreased as  
age advances  because of the possible factors : 
1. Biological factors -   Longevity is low in our country. 
2. Environmental factors  - Patients die earlier due to other causes. 
3. Socio-cultural factors -  Reluctance to treat elderly patients with advanced 
heart failure.  
Annual Incidence of Heart failure (per 1000 population in relation to gender 
and age) 
 
In the Framingham heart study 
Table - 19    Comparative analysis in % 
 Male Female 
Age Framingham 
study 
Present 
study 
Framingham 
study 
Present study 
50-59 3 9 2 6 
80-89 27 2 22 1 
All ages 2.3 17 1.4 15 
 
 Males are affected more than females.  NHANES  1988 – 1994  stated that 
there is increased prevalence of CHF in men aged 70 years.  
In the Framingham study,  case fatality rate was about 35-71  among 1000 
CHF patients. In the present study, case fatality rate was about 36  among 1000 CHF 
patients.   
Cowie et al stated that exertional breathlesseness was a frequent presenting 
symptom and pulmonary rales was the most  frequent sign in CHF. 
 In the present study the most common presenting symptom was 
Breathlessness and it was observed in 99% and most of them suffered from CAD. 
 Most common presenting sign was pulmonary crepitations, seen in around 
98%. Pedal edema was the third most common presenting symptom.  It was seen in 
about 94% of patients. Elevated JVP was seen in 110  of 196 patients. Tender 
hepatomagaly was observed in 80 out of 196 patients. 
 
Comparative analysis of presenting symptoms is given in  
Table No. 20  below. 
Table - 20   Comparative Analysis 
Details of study Breath 
lessness 
Pedal edema JVP Tender 
hepatomagaly 
Pulmonary 
rales 
Framingham Study 92% 85% 64% 42% 90% 
Present study 99% 94% 72% 40% 98% 
 
 In present study, it was noted that, most  of the anaemic patients  presented 
with pedal edema and breathlessness. 
 Heerdinke E, et al, stated that patient who consume NSAIDs had  increased 
risk of congestive heart failure more so in elderly patients.  
 An often neglected subject in the CHF is the use of drugs that are harmful in 
patients with heart failure.  NSAIDs are notorious for provoking decompensation of 
previously stable heart failure. 
 NSAIDs produce salt and water retention, Impaired renal function  can be 
associated with life threatening hyperkalemia and  increased fluid volume. 
 In the present study it was noted that 86 heart failure patients, out of 196 
patients (44%) were precipitated by recent intake of NSAIDs. Next common 
precipitating factor was acute infection (17%) which was evidenced by clinical and 
laborotary means. Anaemia and diet contributed in 15% each. The remaining 9% of 
the patients it was precipitated by arrhythmias.  
 Regarding precipitating factors, 3 Ps are significant. 
1. Prescribers 
2. Patients 
3. Public 
 
PRECIPITATING FACTORS 
 
 
 
 
 
 
1. Non compliance of drugs and diet 
2. Depression  
3. Frustrations 
4. Economical Factors 
Prescribers belonging to complementary 
alternative medicine (CAM) 
CHF PUBLIC CARE 
GIVERS 
Prescribers of Modern 
medicinces 
Non physicians, 
Specialists 
Patients themselves 
  
      Regarding prescribers, complementary alternative medicine practitioners 
may prescribe some native medicine or NSAIDs. That may precipitate CHF. 
Non physicians, or other specialists  also prescribe pain killers and other drugs that 
can  precipitate CHF. 
  
Regarding patients CHF may be precipitated by  
- Poor compliance of drugs and diet due to depression and 
frustrations 
- Economical Factors 
 
Often public-care givers, direct patients to nonconventional medical 
practices.  As a result, patients consume unnecessary medicines and CHF gets 
precipitated. 
The following remedies should be taken to reduce the prevalence of CHF. 
Remedial Measures are furnished in Table No.  given below 
 
Table No : 21 
Educational aspects on CHF for patients – public and practitioners 
 
Patients Patient’s Family Public Practitioners 
Avoid 
1. Excess fluid  
     & Salt 
2. Medications  
  Such as   NSAIDs 
 Advice 
1. Drug compliance 
2.  Behaviour   
    modification 
3. Caring 
Awareness through 
1. TV 
2. Newspapers 
3. Question& 
answers 
Assess 
1.Unnecessary 
drugs 
2. Underlying 
heart disease 
    3. Alcohol 
  4.  Smoking 
 
   
4. Periodic follow 
   up 
 
 3. Urine for 
proteinuria 
 
 
 
So, the patients should be instructed about 
A - Activity reduction 
B - Behaviour modification 
C - Compliance of drugs 
D - Diet modification 
E - Evaluation of other factors 
 
Coming to the etiological factors,  Khardra  et al, observed  CAD as the 
commonest cause of heart failure.  In the SOLVD study CAD accounted for almost, 
75% of the cases of heart failure. CAD and HT were implicated as the cause in over 
70% of cases of heart failure in the Framingham study. Recent Hillington heart 
failure study has identified CAD as the primary etiology in 36% of HF.  
 
In the present study CAD is the most common etiology for CHF.  It comes to 
around 42%.  Next common etiology is RHD. which comes to around 24%,  
Systemic HT is the third common etiology. 
 In the present study, CAD and RHD are the most common etiological factors 
for CHF. 
 
  
 
 
 
 
Etiologiocal aspects   of the Heart failure is shown in Table 22 below. 
Table - 22 
A comparative Analysis : 
Etiology 
Year 
Present 
study 
(2005) 
Teerlink et 
al study 
(1989-91) 
Framingham heart 
study 
(1995) 
Hillington’s  
study 
(1995) 
Ischemic 
CAD 
42% 50% 53.5% 36% 
Non 
Ischemic 
58% 50% 46.5% 64% 
 
 Patients with abnormal waist circumference irrespective of age, size have  
elevated systolic blood pressure and diastolic blood pressure which was also a risk 
factor for developing coronary artery disease. 
 
 The waist circumference was low or below the standards described for men 
and women in 97% in the study population in contrast to Siedell et al (1998).  The 
low waist circumference may reflect their socio-economic status. 
 
 Charney et al  suggested  that BMI > 30 had increased  risk of CHF. 
 In the present study, 8% of the CHF patients had  BMI < 20.  51% of the CHF 
patients had  BMI between  20-25 and 35% of the patients  between  25-30. In 
contrast to Charney et al, in the present study most of the CHF patients had  BMI 
between 20-30.  This may reflect the low socio-economic status of the study 
population. 
 
 
CONCLUSION 
 
1. The  prevalence of congestive heart failure among hospitalized was 3.2 %.   
2. Congestive heart failure was common among the age group of  45 – 65 
years. 
3. Dyspnea and pulmonary crackles were the most common presenting 
symptom and sign respectively. 
4. Drug intake mainly Non steroidal anti inflammatory drugs, anaemia and 
infections were the most common precipitating factors. 
5. Coronary artery disease and Rheumatic heart disease were the most 
common etiological factors  
6. Among young individuals, female predominance was noticed and 
attributable to rheumatic heart disease whereas, the reverse was true in 
middle age and old age.  The later could be due to tobacco related cardiac 
illness or other etiologies. 
7. Waist circumference was in between 80-90 cm in most of the study 
population 
 8. The Body mass index of 171 patients out of the 196 patients included in 
the study was between 20-30. 
9. In hospital, case fatality rate was 3.5% 
 
SUMMARY 
 Congestive heart failure (CHF) a commonly encountered clinical entity was 
studied among the patients admitted in the medical wards over 6 months period.  It 
was carried out, a) to find out the prevalence of congestive heart failure among the 
patients admitted in the hospital, b) to analyse their presenting features & 
precipitating factors c) to correlate the clinical findings with the underlying etiology 
and d) to study outcome of these cases during their hospital stay. 
Among 6072 admissions 196 patients with congestive heart failure  satisfied 
the inclusion criteria. The prevalence rate was 32.28 / 1000 population, and observed 
more in males but not statistically significant.  The case fatality rate among the 
congestive heart failure patients was 3.5% (7/196). 
The most common age group of affected individuals was 45 – 65 years.  
Etiological factors for the congestive heart failure were in the order of  
Coronary artery disease. (42%), Rheumatic heart disease (24%), Systemic 
hypertension (15%) and others    (19%) 
 Most common presenting symptom was breathlessness (99%) and the sign 
was pulmonary crackles.(98%).  Other presenting features  were pedal edema (94%), 
chest pain (82%), oliguria (77%) and tender hepatomegaly (40%). Most common 
precipitating factors noted were NSAIDs intake (44%) followed by infection (17%), 
anaemia (15%), salty diets (15%) and arrthymias (9%). 
  With  better understanding of the pathophysiology of CHF both non 
pharmacological means and the available newer group of drugs made available to  
patients through the 3Ps (patients, prescribers, public caregivers) the quality of 
life of the unfortunate patients could be improved. 
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 PROFORMA 
Prevalence, Pattern, Precipitating factors and Presenting Features of CCF 
S.No.       I.P. No.      : 
Patient’s Name :     Date of Admn  : 
1. Age  :    2. Sex   : 
3. Occupation :    4. Height  :  
5. Body mass Index (Weight / H2 in meter) 6. Weight  :  
7. Waist in cms :    8. Hip in cms  : 
9. Waist / Hip ratio :    10. Socio-economic status  : 
11. Out come :    12. Dyspnea    : 
13. Palpitations :    14. Dyspnea Grade   : 
15. Chest pain :    16. Pedal Oedema     : 
17. Sacral Oedema :    18. Abdominal Pain   : 
19. Abdominal distesion :   20. Anorexia       : 
21. Nausea, vomiting :   22. Cyanosis      : 
23. Oligurea  :   24. Pulmonary rales : 
25. Hepatomegaly :   26. JVP       : 
27. Hypertension  :   28. Smoker       : 
29. Smoker  :   30. Alcoholic      : 
31. Diet   :   32. Anemia      : 
33. Infection  :   34. Coronary heart disease : 
35. Rheumatic heart disease :   36. Dyslipidemia     : 
37. Regular Exercise :   38. Pregnancy  : 
39. Thyrotoxicosis :   40. Hypothyroidism  : 
41. Drug Intake  :   42. NSAID  : 
43. B – Blockers  :   44. Steroids  : 
45. Ca – Channel blockers :   46. Native medicine  : 
47. Arrhythmias  :   48. Infective Endocarditis: 
49. Pulse rate  :   50. R – R   : 
51. B.P   :   52. Hb   : 
53. Echo – EF  :   54. ECG   : 
55. Conclusion  : 
  
ABBREVIATIONS 
 
 CO  - CARDIAC OUTPUT 
 HF  - HEART FAILURE 
 CHF  - CONGESTIVE HEART FAILURE 
 CAD  - CORONARY HEART DISEASE 
 RHD  - RHEUMATIC HEART DISEASE 
 BMI  - BODY MASS INDEX 
 JVP  - JUGULAR VENOUS PULSE 
 RAAS  - RENIN ANGIOTENSIN ALDOSTERONE SYSTEM 
 NSAIDs - NON STEROIDAL ANTI INFLAMMATORY DRUGS 
 
MASTER CHART  ABBREVIATIONS 
 Sex  - Male  - 1 Female  - 2 
 others  - Yes - 1 No  - 2 
 W/H  - Waist Hip Ratio  Dys - Dyspnea 
 Palp  - Palpitation   CP - Chest pain 
 PE  - Pedal edema   Smok - Smoking 
Abd dis - Abdominal Distension  Alco - Alcohol 
DM   - Diabetes mellitus   Hepat - Hepatamegaly 
Amem  - Anaemia    Infe - Infections  
sl.no age sex BMI W/H dys palp cp pe abd d oligur DM smokialcohodiet drug BP hepat anem infn ECG CAD RHD CM Cor pu
1 40 2 19.5 0.9 1 1 1 1 2 1 2 2 2 2 1 2 1 2 2 2 1 2 2 2
2 46 1 20.2 0.8 1 2 2 1 2 2 2 2 2 2 2 1 1 1 2 2 2 2 2 2
3 56 2 40.7 0.8 2 2 1 1 2 1 2 2 2 2 2 2 2 2 1 2 2 1 2 2
4 42 1 18 0.9 1 1 1 2 2 1 2 1 1 1 2 1 1 2 2 2 2 2 2 2
5 40 2 27 0.9 1 2 1 1 1 1 2 2 2 2 2 2 1 2 2 1 1 2 2 2
6 40 2 23 0.9 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 2 1 2 2
7 74 2 19 0.9 2 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2
8 35 1 19 0.9 1 1 2 1 1 1 2 1 2 2 2 2 1 2 2 1 1 2 2 2
9 40 1 22 0.9 1 1 1 1 2 2 2 1 1 1 2 2 1 2 2 2 1 2 2 2
10 19 1 22 0.9 1 1 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 1 2 2
11 55 1 27 1 1 2 2 1 1 1 2 1 1 1 2 2 2 2 2 2 1 2 2 2
12 72 1 23 0.9 1 1 1 1 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2 2
13 63 1 17 0.9 1 2 1 1 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2
14 32 2 20 0.9 1 1 1 1 1 1 2 2 2 2 2 2 1 1 2 2 1 2 2 2
15 14 2 15 0.9 1 1 1 1 1 2 2 2 2 2 1 2 1 2 2 2 1 2 2 2
16 60 1 27 1 1 1 1 1 1 1 1 1 1 2 2 2 1 2 2 1 2 2 1 2
17 55 1 20 0.9 1 2 1 1 1 1 2 1 1 1 2 1 1 2 2 2 2 2 2 2
18 55 2 23 0.9 1 1 1 1 2 1 2 2 2 2 2 2 2 2 2 1 1 2 2 2
19 60 2 25 0.9 1 1 1 1 2 1 1 2 2 2 1 2 1 2 2 2 2 1 2 2
20 60 2 24 0.9 1 1 1 1 2 2 2 2 2 2 1 2 2 2 2 2 1 2 2 2
21 45 2 22 0.9 1 1 2 1 2 1 2 2 2 2 1 2 1 2 2 2 2 1 2 2
22 50 1 21 0.9 1 2 1 1 1 1 2 1 1 2 2 2 1 1 2 2 1 2 2 2
23 55 1 27 0.9 1 2 2 1 1 2 2 1 1 1 2 2 2 2 2 2 1 2 2 2
24 22 2 24 0.9 1 2 2 1 1 1 2 2 2 2 1 2 1 2 2 2 2 1 2 2
25 15 2 21 0.9 1 2 1 1 2 2 2 2 2 1 2 2 1 2 2 2 2 1 2 2
26 50 2 23 1 1 2 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 1 2 2
27 48 2 29 0.9 1 1 1 2 1 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2
28 50 2 24 0.9 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 1 2 2 1 2
29 48 2 20 0.9 1 1 1 2 2 1 2 2 2 2 1 2 1 2 2 2 1 2 2 2
30 55 1 22 0.9 1 1 2 1 1 1 2 1 1 1 2 1 1 2 2 2 2 2 2 2
31 48 2 22 0.9 1 1 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 1 2 2
32 36 2 23 0.9 1 1 1 1 1 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2
33 21 2 21 1 1 2 2 1 2 2 2 2 2 2 1 2 1 2 2 2 2 1 2 2
34 28 2 20 0.9 1 2 1 1 1 1 2 2 2 2 2 2 1 2 1 2 2 1 2 2
35 50 2 22 0.9 1 1 1 1 2 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2
36 60 1 25 0.9 1 1 2 2 2 1 2 2 1 2 2 2 2 1 2 2 1 2 2 2
37 56 2 22 1 1 2 2 1 1 1 2 2 2 2 1 2 1 2 2 2 2 1 2 2
38 14 2 18 1 1 1 2 1 1 1 2 2 2 2 2 2 1 2 2 1 2 1 2 2
39 54 1 20 0.9 1 2 1 1 2 2 2 1 1 2 2 2 2 2 1 2 1 2 2 2
40 58 1 24 1 1 2 2 1 1 1 1 1 1 2 2 2 2 2 1 2 1 2 2 2
41 38 2 23 1 1 1 2 1 1 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2
42 53 1 24 1 1 1 1 1 1 1 1 2 2 1 2 1 1 2 2 2 2 2 2 2
43 50 1 21 0.9 1 1 2 1 2 1 1 2 2 2 1 2 2 2 2 2 1 2 2 2
44 70 2 24 1 1 1 1 1 1 1 2 2 2 2 2 2 1 1 2 2 2 1 2 2
45 40 2 22 0.9 1 1 2 1 2 1 2 2 2 2 1 2 2 2 2 2 2 1 2 2
46 25 1 24 0.9 1 1 2 1 2 2 2 1 1 2 1 2 1 2 2 2 1 2 2 2
47 49 1 24 1 1 1 1 1 2 1 2 1 2 2 1 2 2 2 2 2 1 2 2 2
48 62 1 23 1 1 1 1 1 1 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2
49 47 1 22 0.9 1 2 1 1 2 1 2 1 1 2 2 2 2 2 2 1 1 2 2 2
50 35 2 23 0.9 1 1 1 1 1 1 2 2 2 2 2 1 1 2 1 2 2 2 2 2
51 25 2 22 0.9 1 1 1 1 1 1 2 2 2 1 2 1 1 2 2 2 2 2 2 2
52 65 1 30 1 1 1 1 1 2 1 2 1 1 2 2 2 2 1 2 2 1 2 2 2
53 60 2 24 1 1 1 1 1 1 1 1 2 2 2 2 2 1 2 1 2 2 1 2 2
54 35 1 23 0.9 1 1 2 1 1 2 2 1 1 2 1 2 1 2 2 2 1 2 2 2
55 55 1 24 0.9 1 1 1 1 1 1 2 2 1 2 2 2 1 2 1 2 2 1 2 2
56 70 1 22 0.9 1 1 2 1 2 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2
57 52 2 21 1 1 1 1 1 1 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2
58 45 1 25 0.9 1 1 1 1 1 1 1 1 1 2 2 2 1 2 1 2 1 2 2 2
59 27 1 25 0.9 1 1 2 1 2 1 2 1 1 1 2 2 2 2 2 2 1 2 2 2
60 70 2 25 0.9 1 1 1 1 1 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2
61 50 2 23 1 1 1 1 1 1 1 2 2 2 2 2 2 1 2 2 1 2 1 2 2
62 70 1 22 1 1 2 1 1 1 1 2 1 2 2 1 2 1 2 2 2 1 2 2 2
63 48 1 22 1 1 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2
64 60 1 21 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 2 1 2 2 2
65 52 2 26 1 1 1 1 1 1 1 2 2 2 2 2 1 1 2 1 2 2 2 2 2
66 66 1 23 0.9 1 2 1 1 2 1 2 1 2 2 1 2 1 2 2 2 1 2 2 2
67 60 1 21 1 1 2 1 1 1 1 2 2 2 2 2 2 1 1 2 2 1 2 2 2
68 40 2 21 0.9 1 1 1 1 1 1 1 2 2 2 2 2 1 2 1 2 2 1 2 2
69 56 2 23 1 1 1 1 1 1 1 1 2 2 2 1 2 1 2 2 2 2 1 2 2
70 60 1 25 1 1 1 1 1 2 2 2 1 1 1 2 2 1 2 2 2 1 2 2 2
71 50 1 23 1 1 1 2 1 2 1 2 1 2 2 2 2 2 1 2 2 2 1 2 2
72 85 1 26 1 1 2 1 1 1 1 2 1 1 1 2 2 1 2 2 2 1 2 2 2
73 14 2 18 1 1 1 2 1 1 1 2 2 2 2 2 2 1 2 1 2 2 1 2 2
74 32 1 22 1 1 2 2 1 2 1 2 1 1 1 2 2 1 2 2 2 2 2 2 1
75 70 1 19 1 1 2 2 1 2 2 2 1 1 2 1 2 1 2 2 2 1 2 2 2
76 60 1 23 0.9 1 2 1 1 2 1 1 1 1 1 2 2 1 2 2 2 2 1 2 2
77 70 1 30 1 1 1 1 1 2 1 2 2 2 2 1 2 2 2 2 2 1 2 2 2
78 57 1 22 0.9 1 1 1 1 2 1 2 2 2 2 2 1 2 1 2 2 2 2 2 2
79 58 1 23 1 1 2 1 1 2 1 2 1 1 2 2 2 2 2 2 1 1 2 2 2
80 35 1 24 0.9 1 1 1 1 1 1 2 1 2 2 1 2 1 2 2 2 2 1 2 2
81 65 1 20 0.9 1 1 1 1 2 1 2 1 1 2 2 2 2 2 1 2 1 2 2 2
82 45 1 21 1 1 1 1 1 2 1 2 1 1 2 2 2 2 1 2 2 2 2 1 2
83 43 1 28 1 1 2 1 1 1 2 1 1 1 2 2 1 1 2 1 2 2 2 2 2
84 70 1 23 1 1 2 1 1 2 1 2 1 1 2 1 2 2 2 2 2 2 1 2 2
85 50 2 32 1 1 1 1 1 2 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2
86 15 2 19 1 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 1 2 2
87 38 1 21 1 1 1 2 1 1 2 2 1 1 2 1 2 1 2 2 2 2 1 2 2
88 56 1 30 1 1 1 2 1 1 1 2 1 2 2 2 2 1 2 1 2 1 2 2 2
89 50 1 24 1 1 1 1 1 1 2 1 1 1 2 1 2 2 2 2 2 1 2 2 2
90 35 2 23 0.9 1 1 1 1 1 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2
91 56 1 24 1 1 1 2 1 2 2 2 1 2 2 2 2 2 2 1 2 2 1 2 2
92 16 2 19 1 1 1 2 1 2 1 2 2 2 2 2 2 1 1 2 2 2 2 1 2
93 50 2 23 1 1 1 1 1 1 1 2 2 2 2 2 2 1 1 2 2 2 2 1 2
94 60 2 26 1 1 1 1 1 1 1 1 2 2 2 2 2 1 2 2 1 2 2 2 1
95 28 1 22 1 1 1 1 2 1 1 2 1 2 2 1 2 1 2 2 2 1 2 2 2
96 56 1 27 1 1 1 1 1 1 1 2 1 1 2 2 2 1 2 2 1 1 2 2 2
97 65 1 23 1 1 1 1 1 2 1 2 1 1 2 1 1 2 2 2 2 2 2 2 2
98 72 1 22 1 1 1 1 1 2 2 2 1 2 1 2 2 1 2 2 2 1 2 2 2
99 60 1 21 0.9 1 1 1 1 2 2 2 1 1 2 2 2 2 2 1 2 2 1 2 2
100 37 1 19 1 1 1 1 1 2 1 2 2 1 2 2 2 2 1 2 2 1 2 2 2
101 80 1 16 0.9 1 1 1 1 2 1 2 1 2 2 2 2 1 2 1 2 1 2 2 2
102 55 1 27 1 1 1 1 2 2 1 1 1 1 2 1 2 1 2 2 2 1 2 2 2
103 60 1 22 0.9 1 2 1 1 1 1 1 1 2 2 2 1 1 2 2 1 2 2 2 2
104 48 1 24 0.9 1 1 2 2 1 2 1 1 1 2 1 2 1 2 2 2 1 2 2 2
105 37 1 30 0.9 1 2 1 1 1 1 2 1 1 2 2 2 1 1 2 2 2 2 1 2
106 45 1 24 1 1 1 1 1 1 2 2 1 1 2 1 2 1 2 2 2 1 2 2 2
107 31 1 28 0.9 1 1 1 1 1 1 2 1 2 2 2 2 1 1 2 2 2 1 2 2
108 75 1 22 0.9 1 1 1 1 2 1 1 1 2 2 2 2 2 2 2 2 1 2 2 2
109 50 1 22 0.9 1 1 1 1 1 2 2 1 1 2 1 2 1 2 2 2 1 2 2 2
110 20 1 21 1 1 1 1 1 1 1 2 1 1 2 2 2 1 1 2 2 1 2 2 2
111 53 1 23 0.9 1 1 1 1 1 2 2 1 2 2 1 2 1 2 2 2 1 2 2 2
112 14 2 17 0.9 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 1 2 2
113 21 2 21 1 1 1 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 1 2
114 56 2 29 0.9 1 1 1 1 1 2 2 2 2 2 2 2 1 2 2 1 2 2 1 2
115 13 2 22 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1
116 26 2 23 1 1 1 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2
117 60 2 20 0.9 1 1 2 1 1 1 1 2 2 2 1 1 1 2 2 2 2 2 2 2
118 37 2 22 1 1 1 1 1 2 1 2 2 2 1 2 2 2 2 2 2 2 2 1 2
119 57 1 27 0.9 1 1 1 1 2 1 2 1 1 1 2 2 2 2 2 2 1 2 2 2
120 56 1 26 0.9 1 2 2 1 2 1 2 1 1 2 2 2 2 1 2 2 1 2 2 2
121 53 1 25 1 1 1 1 1 2 1 2 1 1 2 2 2 2 2 1 2 1 2 2 2
122 29 2 24 1 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 2 1 2
123 60 2 26 0.9 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 1 2 2
124 65 2 36 0.9 1 1 1 1 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2
125 65 2 22 0.9 1 2 1 1 1 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2
126 25 2 22 0.9 1 2 1 1 2 1 2 2 2 2 1 2 1 2 2 2 2 1 2 2
127 14 2 19 0.9 1 1 1 1 1 2 2 2 2 2 1 2 1 2 2 2 2 2 1 2
128 60 2 23 0.9 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 2 1 2
129 65 1 23 0.9 1 1 1 1 1 1 1 1 1 2 1 2 1 2 2 2 1 2 2 2
130 26 2 23 1 1 2 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 2 2 1
131 40 2 26 1 1 1 1 1 1 1 2 2 2 1 2 2 1 2 2 2 2 2 1 2
132 63 2 28 1 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 1 2 2
133 55 2 22 1 1 1 1 1 1 1 2 2 2 1 2 1 1 2 2 2 2 2 2 2
134 40 2 21 1 1 1 1 1 1 1 2 2 2 1 2 2 1 2 2 2 2 2 2 1
135 40 2 24 1 1 1 1 1 1 1 2 2 2 2 1 2 2 2 2 2 2 2 1 2
136 65 2 23 0.9 1 2 2 1 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2
137 27 2 39 0.9 1 1 1 1 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2
138 40 2 24 1 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 1 2 1
139 55 1 26 0.9 1 1 1 1 2 1 2 2 2 2 1 2 2 2 2 2 1 2 2 2
140 55 1 26 1 1 1 1 1 1 1 2 1 2 2 2 2 1 1 2 2 1 2 2 2
141 65 1 28 1 1 2 1 1 2 1 2 1 1 2 2 2 2 1 2 2 1 2 2 2
142 50 1 27 1 1 2 1 1 2 1 2 1 2 2 1 2 2 2 2 2 1 2 2 2
143 58 1 25 0.9 1 1 1 1 1 1 2 1 1 1 2 2 1 2 2 2 1 2 2 2
144 41 1 26 1 1 1 1 1 2 1 2 1 2 2 1 2 1 2 2 2 2 2 2 1
145 38 1 26 1 1 1 1 1 2 1 2 1 2 2 1 2 2 2 2 2 1 2 2 2
146 35 1 24 0.9 1 1 1 1 2 1 2 1 2 2 1 2 1 2 2 2 2 2 2 1
147 19 1 20 0.9 1 1 2 1 2 1 2 2 2 2 2 2 2 2 1 2 1 2 2 2
148 85 1 24 0.9 1 1 1 1 2 1 2 1 2 2 1 2 2 2 2 2 1 2 2 2
149 39 2 25 1 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2
150 60 2 23 1 1 1 1 1 1 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2
151 60 2 25 0.9 1 1 1 1 2 1 2 2 2 2 2 2 1 2 1 2 2 2 2 1
152 45 2 21 0.9 1 1 1 2 1 1 2 2 2 2 1 2 1 2 2 2 2 1 2 2
153 22 2 27 0.9 1 1 2 1 1 1 2 2 2 2 1 2 1 2 2 2 2 2 1 2
154 38 2 23 0.9 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 1 2 2 2
155 21 1 25 1 1 1 1 1 2 2 2 1 2 1 2 2 1 2 2 2 1 2 2 2
156 30 1 23 0.9 1 1 1 1 2 1 2 2 2 2 2 2 1 2 2 1 1 2 2 2
157 18 1 17 1 1 1 1 1 2 1 2 2 2 2 1 2 1 2 2 2 1 2 2 2
158 39 1 18 0.9 1 2 2 1 1 2 2 1 1 2 1 2 1 2 2 2 1 2 2 2
159 18 2 19 0.9 1 1 1 1 1 1 2 2 2 2 2 2 1 1 2 2 2 2 1 2
160 75 2 22 0.9 1 1 1 1 1 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2
161 34 2 23 1 1 1 1 1 2 1 2 2 2 2 2 2 1 2 1 2 2 2 2 1
162 20 2 19 0.9 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 2 1 2 2
163 54 1 20 0.9 1 1 1 1 1 1 2 1 1 2 1 2 1 2 2 2 1 2 2 2
164 65 1 24 0.9 1 1 1 1 2 1 1 1 1 1 2 2 2 2 2 2 1 2 2 2
165 75 1 26 1 1 1 1 1 1 1 1 1 2 2 1 2 1 2 2 2 1 2 2 2
166 37 1 27 1 1 2 1 1 2 1 2 2 2 2 1 2 1 2 2 2 2 2 2 1
167 59 1 23 0.9 1 1 1 1 1 1 2 1 1 2 1 2 1 2 2 2 1 2 2 2
168 50 2 24 1 1 1 1 1 1 1 2 2 2 2 1 1 1 2 2 2 2 2 2 2
169 60 2 25 0.9 1 1 1 1 1 1 2 2 2 2 2 2 1 2 1 2 1 2 2 2
170 30 1 20 1 1 1 1 1 1 1 2 1 2 2 1 2 1 2 2 2 1 2 2 2
171 75 1 24 0.9 1 1 2 1 1 1 2 1 1 2 1 2 1 2 2 2 2 2 2 1
172 55 2 19 0.9 1 1 1 1 1 1 2 2 2 2 2 2 1 2 1 2 2 1 2 2
173 48 2 25 0.9 1 1 1 1 2 1 2 2 2 2 1 2 2 2 2 2 2 1 2 2
174 65 2 28 0.9 1 2 1 1 2 1 1 2 2 1 2 2 2 2 2 2 2 2 2 1
175 40 1 26 0.9 1 1 1 1 2 1 2 2 2 2 2 2 2 1 2 2 1 2 2 2
176 45 1 30 1 1 1 1 1 2 1 2 1 2 2 2 2 1 2 1 2 1 2 2 2
177 55 1 26 1 1 2 1 1 2 1 2 1 2 2 1 2 2 2 2 2 1 2 2 2
178 39 1 26 1 1 1 1 1 1 1 2 1 2 2 2 2 1 2 1 2 1 2 2 2
179 53 2 25 0.9 1 1 1 1 1 1 1 2 2 2 2 2 1 1 2 2 2 1 2 2
180 53 2 24 0.9 1 1 1 1 2 1 2 2 2 2 2 2 2 2 1 2 2 2 2 1
181 35 2 24 1 1 1 1 1 1 1 2 2 2 2 1 2 1 2 2 2 1 2 2 2
182 78 1 27 0.9 1 1 1 1 1 1 2 1 2 2 1 2 1 2 2 2 2 2 2 1
183 67 1 24 0.9 1 1 1 1 1 1 2 1 2 1 2 2 1 2 2 2 1 2 2 2
184 62 1 24 1 1 1 1 1 1 1 2 1 2 2 1 2 1 2 2 2 1 2 2 2
185 31 1 28 0.9 1 1 1 1 1 1 2 2 2 2 2 2 1 2 1 2 1 2 2 2
186 58 1 24 1 1 1 1 1 2 1 2 1 1 2 1 2 1 2 2 2 1 2 2 2
187 75 2 24 0.9 1 1 1 1 2 1 2 2 2 1 2 1 1 2 2 2 2 2 2 1
188 55 2 23 0.9 1 1 1 1 1 1 2 2 2 1 2 1 1 2 2 2 2 2 2 2
189 60 1 28 1 1 1 1 1 1 1 2 1 1 2 2 2 1 2 1 2 2 2 2 2
190 45 1 25 1 1 1 1 1 1 1 2 1 2 2 1 2 1 2 2 2 1 2 2 2
191 70 1 24 1 1 1 1 1 1 1 1 1 1 2 2 2 1 2 1 2 2 2 2 1
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194 45 2 25 0.9 1 1 1 1 1 1 2 2 2 2 2 2 1 2 1 2 2 2 2 2
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196 42 2 27 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 1 2 1 2 2
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